Connection

Jean-Charles Soria to Prognosis

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Prognosis.
Jean-Charles Soria
Connection Strength
0.156
Prognosis
  1. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012 May 01; 18(9):2443-51.
    View in: PubMed
    Score: 0.022
  2. Expression of cell cycle biomarkers and telomere length in papillary thyroid carcinoma: a comparative study between radiation-associated and spontaneous cancers. Am J Clin Oncol. 2009 Feb; 32(1):1-8.
    View in: PubMed
    Score: 0.018
  3. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 2021 12; 28(12):3297-3315.
    View in: PubMed
    Score: 0.011
  4. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 2021 03 11; 12(3):258.
    View in: PubMed
    Score: 0.010
  5. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. Eur J Cancer. 2019 03; 109:103-110.
    View in: PubMed
    Score: 0.009
  6. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):66-73.e6.
    View in: PubMed
    Score: 0.009
  7. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 10 20; 36(30):2995-3006.
    View in: PubMed
    Score: 0.009
  8. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
    View in: PubMed
    Score: 0.008
  9. Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep. 2017 08 11; 7(1):7952.
    View in: PubMed
    Score: 0.008
  10. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer. 2017 10; 112:62-68.
    View in: PubMed
    Score: 0.008
  11. Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. Lung Cancer. 2017 10; 112:10-15.
    View in: PubMed
    Score: 0.008
  12. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017 Oct 15; 23(20):6101-6112.
    View in: PubMed
    Score: 0.008
  13. Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Invest New Drugs. 2018 02; 36(1):62-74.
    View in: PubMed
    Score: 0.008
  14. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs. 2017 06; 28(5):540-545.
    View in: PubMed
    Score: 0.008
  15. Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients. Cancer Res. 2017 05 01; 77(9):2222-2230.
    View in: PubMed
    Score: 0.008
  16. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer. 2004 Mar 22; 90(6):1222-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.